| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Cancer Biology, Pediatrics and Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030
Overexpression of the HER2/neu oncogene is associated with tumorigenicity and drug resistance in many types of cancer. Three different human Ewing’s sarcoma cell lines (TC71, RD, and A4573) were found to express high levels of the HER2/neu protein. Transduction of TC71 cells with the E1A gene using an adenoviral vector (Ad-E1A) down-regulated HER2/neu overexpression in those cells and increased cytostasis. E1A-induced apoptosis was demonstrated by both flow cytometric analysis and Western blot analysis using a poly(ADP-ribose) polymerase antibody. After transduction of the E1A gene into these cells, the sensitivity of these cells to VP-16 (etoposide) was enhanced 18-fold and to Adriamycin 5-fold. However, no change was seen in cisplatin sensitivity. E1A also significantly increased topoisomerase II
protein expression, indicating that the up-regulation of topoisomerase II may be one of the mechanisms by which E1A enhanced the sensitivity to topoisomerase II-targeting anticancer drugs, such as VP-16 and Adriamycin, but not cisplatin. In summary, these studies demonstrated that Ad-E1A can down-regulate HER2/neu overexpression and up-regulate topoisomerase II expression in human Ewing’s sarcoma cells, increasing their apoptosis rate and enhancing their sensitivity to VP-16 and Adriamycin.
This article has been cited by other articles:
|
|
 |
|
  D. Oberg, E. Yanover, V. Adam, K. Sweeney, C. Costas, N. R. Lemoine, and G. Hallden Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers Clin. Cancer Res., January 15, 2010; 16(2): 541 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Leitner, K. Sweeney, D. Oberg, D. Davies, E. Miranda, N. R. Lemoine, and G. Hallden Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo Clin. Cancer Res., March 1, 2009; 15(5): 1730 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Wen, S.-A. Cheng, S.-P. Hsuen, Y.-L. Huang, Z.-K. Kuo, H.-F. Lee, C.-H. Kuo, J.-L. Du, and W.-B. Wang SV40 T/t-Common Polypeptide Specifically Induces Apoptosis in Human Cancer Cells that Overexpress HER2/neu Cancer Res., June 1, 2006; 66(11): 5847 - 5857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Verneris, A. Arshi, M. Edinger, M. Kornacker, Y. Natkunam, M. Karami, Y.-a. Cao, N. Marina, C. H. Contag, and R. S. Negrin Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells Clin. Cancer Res., June 15, 2005; 11(12): 4561 - 4570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhou, H. Guan, and E. S. Kleinerman E1A Specifically Enhances Sensitivity to Topoisomerase II{alpha} Targeting Anticancer Drug by Up-Regulating the Promoter Activity Mol. Cancer Res., May 1, 2005; 3(5): 271 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Guan, Z. Zhou, H. Wang, S.-F. Jia, W. Liu, and E. S. Kleinerman A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model Clin. Cancer Res., April 1, 2005; 11(7): 2662 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Guan, S.-F. Jia, Z. Zhou, J. Stewart, and E. S. Kleinerman Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo Clin. Cancer Res., March 1, 2005; 11(5): 2008 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Frisch E1A as a Tumor Suppressor Gene: Commentary re S. Madhusudan et al. A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. Clin Cancer Res 2004;10:2905-2907. Clin. Cancer Res., May 1, 2004; 10(9): 2905 - 2907. [Full Text] [PDF]
|
|
|
|
|
|
B. Fuchs, C. Y. Inwards, and R. Janknecht Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing's Sarcoma Clin. Cancer Res., February 15, 2004; 10(4): 1344 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsunobu, K. Tanaka, Y. Matsumoto, F. Nakatani, R. Sakimura, M. Hanada, X. Li, Y. Oda, I. Naruse, H. Hoshino, et al. The Prognostic and Therapeutic Relevance of p27kip1 in Ewing's Family Tumors Clin. Cancer Res., February 1, 2004; 10(3): 1003 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhou, R.-R. Zhou, H. Guan, C. D. Bucana, and E. S. Kleinerman E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model Mol. Cancer Ther., December 1, 2003; 2(12): 1313 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. Schiffer, S. Gebhard, C. K. Heimerdinger, A. Heling, J. Hast, U. Wollscheid, B. Seliger, B. Tanner, S. Gilbert, T. Beckers, et al. Switching Off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission Cancer Res., November 1, 2003; 63(21): 7221 - 7231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Portella, R. Pacelli, S. Libertini, L. Cella, G. Vecchio, M. Salvatore, and A. Fusco ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5027 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-P. Lee, D.-I. Tai, S.-L. Tsai, C.-T. Yeh, Y. Chao, S.-D. Lee, and M.-C. Hung Adenovirus Type 5 E1A Sensitizes Hepatocellular Carcinoma Cells to Gemcitabine Cancer Res., October 1, 2003; 63(19): 6229 - 6236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Cook, T. A. Miura, D. N. Ikle, A. M. Lewis Jr., and J. M. Routes E1A Oncogene-induced Sensitization of Human Tumor Cells to Innate Immune Defenses and Chemotherapy-induced Apoptosis in Vitro and in Vivo Cancer Res., June 15, 2003; 63(12): 3435 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ozaki, K.-L. Schaefer, D. Wai, R. Yokoyama, S. Ahrens, R. Diallo, T. Hasegawa, T. Shimoda, S. Hirohashi, A. Kawai, et al. Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients Ann. Onc., October 1, 2002; 13(10): 1656 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Portella, S. Scala, D. Vitagliano, G. Vecchio, and A. Fusco ONYX-015, an E1B Gene-Defective Adenovirus, Induces Cell Death in Human Anaplastic Thyroid Carcinoma Cell Lines J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2525 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shao, E. M. Tsai, K. Wei, R. von Lindern, Y.-H. Chen, K. Makino, and M.-C. Hung E1A Inhibition of Radiation-induced NF-{kappa}B Activity through Suppression of IKK Activity and I{kappa}B Degradation, Independent of Akt Activation Cancer Res., October 1, 2001; 61(20): 7413 - 7416. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
